Pivotal Phase III data at ASCO show Roche’s Tecentriq helps certain people with early lung cancer live significantly longer without their disease returning

NEXT STORY
OSE Immunotherapeutics and Boehringer Ingelheim Present Positive Phase 1 Results with First-in-Class SIRPα inhibitor BI 765063 in Advanced Solid Tumors at ASCO 2021
PREV STORY
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Arcimoto, Churchill, Emergent BioSolutions, and Verus International and Encourages Investors to Contact the Firm
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Pivotal Phase III data at ASCO show Roche’s Tecentriq helps certain people with early lung cancer live significantly longer without their disease returning

NEXT STORY
OSE Immunotherapeutics and Boehringer Ingelheim Present Positive Phase 1 Results with First-in-Class SIRPα inhibitor BI 765063 in Advanced Solid Tumors at ASCO 2021
PREV STORY
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Arcimoto, Churchill, Emergent BioSolutions, and Verus International and Encourages Investors to Contact the Firm
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Clarus Therapeutics Appoints Dr. Zhanna Jumadilova as Chief Clinical Development Officer

author_avatar
NASDAQ Market News

Sera Prognostics Collaborates with Christiana Care Health System to Launch New Preterm Birth Study with PreTRM® Test

AVERT PRETERM TRIAL studies the impact of interventions based on early risk identificationSALT LAKE ...

author_avatar
NASDAQ Market News

Pfizer and BioNTech Achieve First Authorization in the World for a Vaccine to Combat COVID-19

author_avatar
NASDAQ Market News